**APPENDIX TABLE 3.** Logistic regression predicting a shift to mild/no impairment (SDS subscale score ≤3) at week 8 (LOCF) based on early improvement for patients with marked/extreme impairment (≥7) at baseline: intent-to-treat population

|  |  |  |  |
| --- | --- | --- | --- |
| SDS subscale | Treatment group | Odds ratio (95% CI) | *P* value |
| Early improvement at week 2 |  |  |  |
| Work/studies | Placebo Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dAll | 4.67 (2.698, 8.071)4.34 (2.345, 8.046)8.14 (4.439, 14.931)5.42 (3.884, 7.563) | < .0001 |
|  | < .0001 |
|  | < .0001 |
|  | < .0001 |
| Social life/leisure activities | Placebo Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dAll | 6.73 (4.088, 11.065) | < .0001 |
|  | 3.35 (1.999, 5.598) | < .0001 |
|  | 5.72 (3.504, 9.325) | < .0001 |
|  | 5.21 (3.917, 6.941) | < .0001 |
| Family life/home responsibilities | Placebo Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dAll | 5.65 (3.398, 9.378)3.69 (2.151, 6.317)5.28 (3.191, 8.754)4.92 (3.656, 6.616) | < .0001< .0001< .0001< .0001 |
| Early improvement at week 4 |  |  |  |
| Work/studies | Placebo Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dAll | 16.33 (8.510, 31.334)12.06 (5.858, 24.809)14.72 (7.366, 29.411)14.52 (9.818, 21.467) | < .0001< .0001< .0001< .0001 |
| Social life/leisure activities | Placebo Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dAll | 19.96 (10.985, 36.256)12.94 (6.923, 24.186)14.68 (8.333, 25.851)15.28 (10.908, 21.395) | < .0001< .0001< .0001< .0001 |
| Family life/home responsibilities | Placebo Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dAll | 12.40 (6.971, 22.069)7.21 (3.911, 13.278)13.81 (7.761, 24.561)11.01 (7.872, 15.412) | < .0001< .0001< .0001< .0001 |

CI, confidence interval; LOCF, last observation carried forward; SDS, Sheehan Disability Scale.